# NRx Pharmaceuticals (NRXP) — News

NRXP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nrxp/news

## Recent headlines

- [Nrx Pharmaceuticals - All requested changes classified as "minor" before Nov 10, 2026 - GDUFA goal date](https://www.ainvest.com/news/nrx-pharmaceuticals-requested-classified-minor-nov-10-2026-gdufa-goal-date-2610) — AInvest Wire, Oct 15, 2026
  NRx Pharmaceuticals (Nasdaq: NRXP) has made progress toward addressing regulatory requirements ahead of the November 10, 2026 GDUFA goal date for its pending drug applications. The company recently received a favorable preliminary bioequivalence determination from the FDA for its preservative-free…
- [Nrx Pharmaceuticals announces receipt of FDA labeling review letter for preservative-free ketamine](https://www.ainvest.com/news/nrx-pharmaceuticals-announces-receipt-fda-labeling-review-letter-preservative-free-ketamine-2610) — AInvest Wire, Oct 15, 2026
- [Europe's STOXX 600 pares gains after US CPI, last up 0.46%](https://www.ainvest.com/news/europe-stoxx-600-pares-gains-cpi-0-46-2610) — AInvest Wire, Oct 14, 2026
  European stocks trimmed gains on Thursday as investors digested the latest U.S. inflation data, which showed a 0.4% rise in consumer prices for January, bringing the annual rate to 7.2% . The pan-European STOXX 600 index had earlier risen 0.46% but pared those gains as traders weighed the…
- [Nrx Pharmaceuticals - FDA reclassifies ANDA amendment for preservative-free ketamine to minor amendment](https://www.ainvest.com/news/nrx-pharmaceuticals-fda-reclassifies-anda-amendment-preservative-free-ketamine-minor-amendment-2609) — AInvest Wire, Sep 15, 2026
  NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has received updated feedback from the U.S. Food and Drug Administration (FDA) regarding its Abbreviated New Drug Application (ANDA) for preservative-free ketamine. The FDA has reclassified a previously identified issue related to the luer lock vial as a…
- [Nrx Pharmaceuticals - FDA revises GDUFA goal date for ANDA amendment to November 10, 2026](https://www.ainvest.com/news/nrx-pharmaceuticals-fda-revises-gdufa-goal-date-anda-amendment-november-10-2026-2609) — AInvest Wire, Sep 15, 2026
  The U.S. Food and Drug Administration (FDA) has revised the goal date for the review of Nrx Pharmaceuticals' Abbreviated New Drug Application (ANDA) amendment to November 10, 2026 . This update adjusts the previously established timeline for the agency's evaluation of the amendment, which pertains…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).